Home
News
Create
Screeners
Insights
Sat Kartar Life
201.
15
+3.95
(+2.00%)
Market Cap
₹316.71 Cr
PE Ratio
18.16
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+2.00%
1M
+21.47%
6M
+5.37%
1Y
+43.17%
5Y
+24.51%
View Company Insights
Latest news about Sat Kartar Life
Sat Kartar Life Submits FY26 Earnings Call Transcript With Strategic Growth Roadmap
1 day ago
Yesterday
Sat Kartar Life Limited filed the transcript of its H2 and FY26 Earnings Conference Call with NSE under Regulation 30 of SEBI (LODR) Regulations 2015. Management reported 23% revenue growth crossing ₹200 crore, 73% EBITDA growth, and 74% PAT growth for FY26, while outlining a dual-engine growth strategy combining its core Ayurveda product business with a new hospital vertical targeting 300 beds by FY27 end and 1,000 beds by FY28, supported by a non-exclusive partnership with Jeena Sikho and ongoing expansion into the US market through its Plantomed subsidiary.
Sat Kartar Life Limited Receives NSE In-Principle Approval for Equity Share Issuance via Warrant Conversion
1 day ago
Yesterday
Sat Kartar Life Limited Expands into Curated Spiritual Offerings and Wellness-Related Products
1 day ago
Sat Kartar Life Limited Receives NSE No-Objection for Reclassification of SK Sarthi Private Limited from Promoter Group to Public Category
3 days ago
Sat Kartar Life FY26 PAT Surges 74.31% to ₹17.10 Cr; Targets ₹500 Cr Revenue by FY28
3 days ago
More news about Sat Kartar Life
05
May 26
Sat Kartar Life Limited Promoters Declare No Share Encumbrance for Financial Year Ended March 31, 2026
Sat Kartar Life Limited (formerly Sat Kartar Shopping Limited) has filed a declaration with NSE confirming that its promoters and persons acting in concert have not made any encumbrance on their shares for the financial year ended March 31, 2026. The declaration was submitted by promoter Manprit Singh Chadha on April 1, 2026, and forwarded to NSE by Company Secretary Sonal Seth on April 3, 2026. The filing is in accordance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Sat Kartar Life
201.
15
+
3.
95
(+
2.
00
%)
1 Year Returns:
+43.17%
Industry Peers
Sun Pharmaceutical
1,847.90
(+
0.
74
%)
Divis Laboratories
6,710.50
(+
0.
12
%)
Torrent Pharmaceuticals
4,380.80
(+
0.
41
%)
Cipla
1,347.00
(-
1.
12
%)
Lupin
2,379.50
(-
3.
28
%)
Dr Reddys Laboratories
1,293.90
(-
1.
05
%)
Mankind Pharma
2,430.80
(+
2.
34
%)
Zydus Life Science
940.05
(-
0.
03
%)
Aurobindo Pharma
1,487.30
(+
0.
58
%)
Alkem Laboratories
5,585.50
(-
0.
09
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO